PARP signalling: A link between diabetes, inflammation and periodontal bone loss

Summarised from:

Role of poly(ADP-ribose) polymerase activation in the pathogenesis of periodontitis in diabetes
(Journal of Clinical Periodontology; doi: 10.1111/jcpe.12758)

Authors:

Kei Adachi , Shin-Ichi Miyajima , Nobuhisa Nakamura , Megumi Miyabe , Yasuko Kobayashi , Toru Nishikawa , Yuki Suzuki , Takeshi Kikuchi , Shuichiro Kobayashi , Tomokazu Saiki  , Makoto Mizutani , Norikazu Ohno , Toshihide Noguchi , Akio Mitani , Tatsuaki Matsubara , Keiko Naruse

Summarised by:

Dr Varkha Rattu

Research Topic:

Background + Aims

  • Poly(ADP-ribose) polymerase (PARP) is an enzyme involved in detecting DNA damage and co-ordinating repair. Excessive activation can promote inflammation and deplete cellular energy; diabetes may amplify this process through nitrosative stress (damage caused by excessive reactive nitrogen compounds such as peroxynitrite).
  • This study aimed to:
    • Determine whether PARP activation contributes to diabetes-aggravated periodontitis and whether inhibiting this enzyme reduces periodontal inflammation and bone destruction.

Materials + Methods

  • The study used 48 male Sprague–Dawley rats, with diabetes induced in half using streptozotocin, which damages insulin-producing pancreatic cells.
  • 2-weeks later, periodontitis was induced by placing a nylon ligature around one upper second molar. The corresponding tooth on the opposite side remained unligated as a control.
  • Half of the diabetic and non-diabetic rats received the PARP inhibitor 1,5-isoquinolinediol, administered by daily injection at 3 mg/kg for 2-weeks, starting when the ligature was placed.
  • Gingival PARP activity was assessed by staining for poly(ADP-ribose), the product formed when PARP is activated.
  • Researchers measured inflammatory cell infiltration, inflammatory gene expression and nitrotyrosine, a marker of nitrosative stress.
  • Micro-CT imaging assessed alveolar bone loss. Blood glucose, HbA1c, body weight and circulating white blood cells were also measured.

Results

  • Diabetes and periodontitis each increased gingival PARP activity.
  • Diabetic rats with periodontitis had approximately:
    • 1.5 times as many PARP-active cells as non-diabetic rats with periodontitis.
    • 1.5 times as many gingival monocytes/macrophages (immune cells involved in inflammatory responses)
  • PARP inhibition:
    • Reduced monocyte/macrophage infiltration in both diabetic and non-diabetic rats with periodontitis.
    • Suppressed elevated expression of TNF-α (an inflammatory signalling protein) and iNOS (an enzyme that produces nitric oxide) in the diabetic periodontal tissues,
    • Reduced nitrotyrosine-positive gingival cells by approximately 56% in diabetic rats with periodontitis.
  • Untreated diabetic rats had greater measured bone loss than non-diabetic rats with periodontitis (1.19 versus 0.88 mm). PARP inhibition reduced the bone-loss measure by approximately 32% in diabetic rats and 24% in non-diabetic rats.
  • Blood glucose and HbA1c were not significantly altered, suggesting that the periodontal benefits were not explained by improved glycaemic control.

Limitations

  • The short-term, chemically induced diabetes model does not fully reproduce chronic human diabetes and periodontitis.
  • Treatment began at disease induction, so the study did not establish whether PARP inhibition reverses established periodontal destruction.
  • Individual analyses used relatively small numbers of animals.
  • Inflammatory changes were assessed primarily through gene expression. Corresponding inflammatory proteins and anti-inflammatory pathways were not comprehensively evaluated.
  • The study did not establish an effective human dose, long-term safety or benefit alongside conventional periodontal treatment.

Conclusion

  • PARP activation appears to contribute to the inflammatory and nitrosative processes that aggravate periodontal disease in diabetes. Its inhibition reduced tissue damage in this rat model, identifying a potential therapeutic target that requires further investigation before clinical application.
Read the full article Back to Research

Research  |  30.08.17

clock icon 5 mins to read

Share this page:

Copy Link

You might also like...

Events

Periodontitis-Diabetes Hub x #DiabetesChat

Hosted by #diabeteschat, join Dr Varkha Rattu and the team behind the Periodontitis-Diabetes Hub for an insightful discussion exploring the importance of managing periodontitis and diabetes.

Read more

Events

Oral Health Challenges Among People Living With Diabetes

Dr Antoniszczak will present a lecture about the oral health challenges among people living with diabetes. This lecture explores the key challenges faced by individuals living with diabetes, focusing on…

Read more

Events

Periodontitis-Diabetes Hub x #DiabetesChat

Hosted by #diabeteschat, join Dr Varkha Rattu and the team behind the Periodontitis-Diabetes Hub for an insightful discussion exploring the importance of managing periodontitis and diabetes.

Read more

Events

Oral Health Challenges Among People Living With Diabetes

Dr Antoniszczak will present a lecture about the oral health challenges among people living with diabetes. This lecture explores the key challenges faced by individuals living with diabetes, focusing on the relationship between diabetes and oral health.

Read more
icon1 services

Periodontitis is the 6th most prevalent condition globally

icon1 services

Periodontitis and diabetes are bidirectionally linked

icon1 services

Diabetic complications are increased if you have both diseases

icon1 services

Successful periodontal treatment can improve blood glucose control

icon1 services

Periodontitis is the 6th most prevalent condition globally

icon1 services

Periodontitis and diabetes are bidirectionally linked

icon1 services

Diabetic complications are increased if you have both diseases

icon1 services

Successful periodontal treatment can improve blood glucose control

Our Team

Team - The Periodontitis-Diabetes Hub

Dr Varkha Rattu

Founder & Periodontology Co-Lead

Team - The Periodontitis-Diabetes Hub

Dr Amar Puttanna

Diabetes Co-Lead

Team - The Periodontitis-Diabetes Hub

Dr Rajeev Raghavan

Diabetes Co-Lead

Team - The Periodontitis-Diabetes Hub

Professor Mark Ide

Periodontology Co-Lead

Team - The Periodontitis-Diabetes Hub

Professor Luigi Nibali

Periodontology Co-Lead

Team - The Periodontitis-Diabetes Hub

Dr Dominika Antoniszczak

Education & Support Advisor

Team - The Periodontitis-Diabetes Hub

Dr Jasmine Loke

Clinical Content Advisor

Team - The Periodontitis-Diabetes Hub

Dr Mira Shah

Patient Resource Advisor

Team - The Periodontitis-Diabetes Hub

Elaine Tilling

Outreach & Communications Lead

Team - The Periodontitis-Diabetes Hub

Dr Varkha Rattu

Periodontitis-Diabetes Hub Position: Founder & Periodontology Co-Lead

Team - The Periodontitis-Diabetes Hub

Dr Amar Puttanna

Periodontitis-Diabetes Hub Position: Diabetes Co-Lead

Team - The Periodontitis-Diabetes Hub

Dr Rajeev Raghavan

Periodontitis-Diabetes Hub Position: Diabetes Co-Lead

Team - The Periodontitis-Diabetes Hub

Professor Mark Ide

Periodontitis-Diabetes Hub Position: Periodontology Co-Lead

Team - The Periodontitis-Diabetes Hub

Professor Luigi Nibali

Periodontitis-Diabetes Hub Position: Periodontology Co-Lead

Team - The Periodontitis-Diabetes Hub

Dr Dominika Antoniszczak

Periodontitis-Diabetes Hub Position: Education and Support Advisor

Team - The Periodontitis-Diabetes Hub

Dr Jasmine Loke

Periodontitis-Diabetes Hub Position: Clinical Content Advisor

Team - The Periodontitis-Diabetes Hub

Dr Mira Shah

Periodontitis-Diabetes Hub Position: Patient Resource Advisor

Team - The Periodontitis-Diabetes Hub

Elaine Tilling

Periodontitis-Diabetes Hub Position: Outreach and Communications Lead

View All